LEGNLegend Biotech Corpvs its industry peers
A metric-by-metric comparison of Legend Biotech Corp against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LEGN본 종목 | $6.5B#1 | — | 6.4x#1 | 6.3x#1 | 64.0%#1 | -67.7%#7 | -13.3%#6 | -29.2%#5 | — | — | -48.9%#1 | — |
| LGNDZ | — | — | — | — | 60.4%#2 | 3186.6%#1 | 15.3%#1 | 12.9%#1 | 3.0%#1 | — | — | — |
| LGNXZ | — | — | — | — | 60.4%#2 | 3186.6%#1 | 15.3%#1 | 12.9%#1 | 3.0%#1 | — | — | — |
| LGNYZ | — | — | — | — | 60.4%#2 | 3186.6%#1 | 15.3%#1 | 12.9%#1 | 3.0%#1 | — | — | — |
| LGNZZ | — | — | — | — | 60.4%#2 | 3186.6%#1 | 15.3%#1 | 12.9%#1 | 3.0%#1 | — | — | — |
| LGVN | $80M#2 | — | 7.7x#2 | 66.6x#2 | -49.9%#7 | -42.1%#6 | -1942.2%#7 | -218.3%#7 | -4923.3%#5 | — | — | — |
| LIANY | — | — | — | — | — | 43.8%#5 | — | -54.5%#6 | — | — | — | — |
| LIFD | — | — | — | — | -1.1%#6 | -1238.3%#8 | 2.5%#5 | -353.7%#8 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice